Biomarkers of Cardiovascular Complications in Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-09-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Identification of new retention solutes associated with cardiovascular (CV) toxicity in Chronic Kidney Disease (CKD) patients will help to better understand the pathophysiological mechanisms at stake and to prevent CKD-associated mortality and morbidity. For a molecule to be defined as a toxic retention solute, plasma accumulation in the course of CKD has to be demonstrated but also proof needs to be made that plasma accumulation during CKD is indeed associated with an increased risk of CV complications. Moreover, precise determination of the plasma concentration has to be performed in order to later study in vitro and in vivo the toxic mechanisms involved. Based on previous results of plasma proteome analysis using mass spectrometry, a previous study has selected 10 promising protein candidates. These proteins accumulated in the plasma of patients during CKD progression and are known to be associated with CV events in non-CKD patients. The objective of the present study is now to 1) evaluate the association of the plasma accumulation of the 10 retention solutes with CV complications in CKD patients and 2) determine their plasma concentration using ELISA. One hundred and seventy six patients with advanced CKD will be included and divided in 2 groups: 44 patients with history of CV complications in the past 4 years and 132 patients free of any CV complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Cardiovascular Biomarkers in Patients With Kidney Disease

NCT06037759

Haemodialysis Complication Major Adverse Cardiac Events

NOT_YET_RECRUITING

Extracellular Vesicles as Biomarkers for Chronic Renal Failure

NCT04700631

Chronic Renal Failure Urinary Extracellular Vesicle

COMPLETED NA

Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.

NCT01579032

Arterial Stiffness CHRONIC RENAL FAILURE Left Ventricular Hypertrophy

COMPLETED

Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients

NCT02207153

Endstage Renal Disease

COMPLETED

Kidney Disease Biomarkers

NCT00255398

Kidney Disease Glomerular Disease Idiopathic Nephrotic Syndrome +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiovascular complication

patients with history of CV complications in the past 4 years had biological determination

Biological determination

Intervention Type DIAGNOSTIC_TEST

Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients

No cardiovascular complication

patients free of any CV complications had biological determination

Biological determination

Intervention Type DIAGNOSTIC_TEST

Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological determination

Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient with stage 4 or 5 CKD.

Exclusion Criteria

* patient with stage 1, 2 or 3 CKD
* patient with solid tumor
* patient with malignant blood disease
* patient with acute kidney disease in the past 3 months
* patient with acute glomerulonephritis in the past 6 months.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No